Esra Cengiz

Esra Cengiz

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in Turkish Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
IDİbRahim Halil Dikici
İbRahim Halil Dikici
ECEsra Cengiz
Esra Cengiz
Background: To compare the increase in platelet count after the transfusion of apheresis and pooled platelet suspensions among patients in the internal medicine intensive care unit. Methods Patients who received platelet suspension transfusions and were followed up at the internal medicine intensive care unit at Mehmet Akif Inan Training and Research Hospital were evaluated. The patient's platelet counts were administered apheresis, and pooled platelet suspensions were recorded before and after transfusion. The increase in platelet count was calculated. The two groups were statistically compared. Results: A total of 4,701 platelet suspension transfusions were performed at our hospital between January 1, 2020, and December 31, 2023. Of these transfusions, 2,990 belonged to pooled platelet suspensions and 1,711 to apheresis platelet suspensions. Conclusion: Platelet suspension transfusion is frequently used in patients receiving internal medicine intensive care. However, there is an ongoing debate concerning whether apheresis or pooled platelet transfusion is more effective in increasing platelet count. In this study, we found a significantly higher increase in platelet count among patients in the internal medicine intensive care unit after apheresis platelet suspension transfusion than pooled platelet suspension transfusion.

3 November 2026 in Upsala Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
ECEsra Cengiz
Esra Cengiz
EKEkin Kırcalı
Ekin Kırcalı
RARifat Furkan Aydın
Rifat Furkan Aydın
MÇMurat Çınarsoy
Murat Çınarsoy
Background: Daratumumab, an immunoglobulin G kappa (IgG-κ) monoclonal antibody, can co-migrate with endogenous M-protein on serum immunofixation (IF), producing IgG-κ bands that may be misinterpreted as residual disease. We therefore evaluated treatment responses and the prognostic impact of daratumumab-associated IgG-κ IF positivity on progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Methods: We retrospectively analyzed 108 patients with MM treated with daratumumab-containing regimens at any line of therapy between January 2014 and January 2024. Serum IF IgG-κ positivity was assessed both at the first response assessment and during continued treatment. Treatment responses were classified according to the International Myeloma Working Group (IMWG) criteria, and PFS and OS were analyzed using the Kaplan–Meier method, the log-rank test, and multivariable Cox proportional hazards regression. Results: IgG-κ IF positivity was detected in 85 patients (78.7%) at first response, and the overall response rate to daratumumab was 64.8%. Patients positive at first response had longer PFS (14.0 vs. 7.0 months; P = 0.048) and higher very good partial response/complete response rates (65.9% vs. 43.5%; P = 0.058). In non–IgG-κ myeloma, treatment-emergent positivity was associated with a markedly higher deep-response rate (88.5% vs. 44.2%; P < 0.001) and a reduced risk of progression (hazard ratio 0.17; 95% confidence interval 0.03–0.74; P = 0.018). On multivariable analysis, older age independently predicted mortality, whereas persistent IF positivity did not worsen survival. Conclusions: IgG-κ IF positivity during daratumumab therapy should not be interpreted as residual disease in isolation; a substantial proportion likely reflects therapeutic antibody interference. Recognizing this interference is important to avoid overestimating residual disease and misclassifying treatment response, and confirmatory assays should be used where available.



29 January 2024 in Turkish Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
ECEsra Cengiz
Esra Cengiz
FCFerda Can
Ferda Can
AGAhmet Kursad Gunes
Ahmet Kursad Gunes
FCFunda Ceran
Funda Ceran
SDsimten dağdaş
simten dağdaş
IDİmDat Di̇lEk
İmDat Di̇lEk
Background This study aimed to evaluate the efficacy and side effects of bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment, which is frequently preferred in primary care in patients with multiple myeloma in our country, with two applications per week and one application per week. Methods A total of 141 patients who received VCD in the induction treatment of newly diagnosed multiple myeloma were retrospectively reviewed and analyzed. Both treatment groups were evaluated in terms of efficacy and side effects. Results A total of 141 patients with newly diagnosed multiple myeloma who received VCD in induction therapy were included in the study. The median age was 62 years. Among the 141 patients included in the study, 57 received treatment two days a week, and 84 received treatment one day a week. Sixty-one (43.3%) patients were female and 80 (56.7%) were male. There was no significant difference between the two groups regarding post-treatment response rates after the 2nd cycle VCD regimen (p=0.378) and the 4th cycle VCD regimen (p=0.965). Patients receiving weekly VCD regimens had a significantly higher rate of receiving other regimens, and the additional VCD regimen of autologous stem cell transplant (ASCT) was significantly higher in patients who received a VCD regimen twice a week compared to the other group (p

31 July 2021 in Journal of Contemporary Medicine
Verified
Journal Article
Closed access
PDF file
MAMuhammet Arslan
Muhammet Arslan
HAHalil Serdar Aslan
Halil Serdar Aslan
PÇPınar Çakmak
Pınar Çakmak
MAMehmet Alpua
Mehmet Alpua
ECEsra Cengiz
Esra Cengiz
NYNagihan Yalçin
Nagihan Yalçin
Aim: The aim of this study was to compare the diagnostic adequacy of thyroid samples obtained with 22-Gauge and 27-Gauge needles. Materials and Methods: From January 2019 to December 2019, 860 patients with thyroid nodules who underwent ultrasound-guided fine-needle biopsies were included in this retrospective study. The results of the samples taken were classified cytologically according to the Bethesda 2017classification. Sample adequacy rates were calculated for each group and compared using chi-square tests. Results: Our cytological results were reported as 157 (18,3%) inadequate materials (Bethesda1). There were no statistically significant differences among the adequacy rates achieved with 22- and 27-gauge needles (80.4% and 83.2%, respectively; P>0.05). There was no significant or permanent complication. Conclusion: There was no difference between 22 and 27-Gauge needle sizes in diagnostic adequate sample. Prospective randomized controlled studies are needed to examine the relationships between nodule, needle, and patient dependent variables.